Find the investors funding Health Seed rounds
326,000+ VC, angel and family-office profiles — direct emails, check sizes and stage filters.
SRTD raises €31.5M seed round to develop cell-selective RNA therapies - European Biotechnology Magazine
SRTD is focused on developing cell-selective RNA therapies. This funding round will support their innovative approach to RNA technology, which aims to enhance therapeutic efficacy while minimizing side effects.
SRTD raises €31.5M seed round to develop cell-selective RNA therapies European Biotechnology Magazine
| Nov 13, 2026 | NeuralSat | $3.1M | — | Germany |
| Nov 13, 2026 | Gama | $15.9M | Seed | Germany |
| Nov 12, 2026 | Course Corrected | $85.0M | — | Germany |
| Nov 12, 2026 | SE3 Labs | $30.0M | — | Germany |
You just read who funded SRTD. The same database has the investors behind every other round — with verified emails, check sizes and the stages they actually write at.
Free account: 15 investor contact unlocks a month, no card required.